Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added; the previous notices about government funding lapse and operating status (Revision: v3.4.1) have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding status notice informing users about potential processing delays and the NIH Clinical Center's status, and updated the site revision to v3.4.1 (removing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedUI changes include adding a 'Show glossary' option and updates to page metadata such as 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange Detected- Revision: v3.3.4 updated from v3.3.3.SummaryDifference0.0%

- Check64 days agoChange DetectedLocations now list multiple states (Arizona, California, Florida, Georgia, Kansas, Michigan, Minnesota, New York, North Carolina, Ohio, Oregon, Texas, Washington), expanding trial site access. Revision: v3.3.3 appears after v3.3.2.SummaryDifference1%

- Check85 days agoChange DetectedA new revision tag 'Revision: v3.3.2' is shown and the prior 'Revision: v3.3.1' tag is removed. This is a minor administrative update that does not change study information or user-facing functionality.SummaryDifference0.0%

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.